Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 83%
In fiscal 2025, RIGEL PHARMACEUTICALS INC reported revenue of $294M, up 64.1% year over year. Operating margin was 42.6% and net margin 124.7%, on a free-cash-flow margin of n/a with capital expenditure at n/a of revenue. Every figure is computed directly from RIGL's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $294M | 42.6% | 124.7% |
| FY2024 | $179M | 13.5% | 9.8% |
| FY2023 | $117M | -17.5% | -21.5% |
| FY2022 | $120M | -46.2% | -48.7% |
| FY2021 | $149M | -8.4% | -12.0% |
How does RIGL compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.